Trials / Unknown
UnknownNCT03088280
Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen
Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg vs. 6mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Hospital Geral de Fortaleza · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Single-center, prospective, randomized, open-label clinical trial to evaluate the 1-year efficacy and safety of rATG 3mg/kg compared to 6mg/kg in low to moderate immunological risk patients receiving low exposure tacrolimus plus everolimus (EVL) in a steroid-free protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thymoglobulin | reduced dose (3mg/Kg) |
Timeline
- Start date
- 2015-06-30
- Primary completion
- 2018-01-10
- Completion
- 2020-01-01
- First posted
- 2017-03-23
- Last updated
- 2019-02-22
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT03088280. Inclusion in this directory is not an endorsement.